MedTrace Logo

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00275132 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2014-12-03

No results posted yet for this study

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether erlotinib is more effective than a placebo in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works compared to a placebo in treating patients with stage III or stage IV non-small cell lung cancer.

Conditions

Interventions

DRUG

erlotinib hydrochloride

Tarceva (OSI-774, erlotinib) PO 150 mg daily

DRUG

Matched placebo

Matched placebo PO daily

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Principal Investigators

  • Siow M Lee, MD, PhD, FRCP · University College London Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00275132 on ClinicalTrials.gov